These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21366404)

  • 21. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
    Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
    Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.
    Kottke T; Diaz RM; Kaluza K; Pulido J; Galivo F; Wongthida P; Thompson J; Willmon C; Barber GN; Chester J; Selby P; Strome S; Harrington K; Melcher A; Vile RG
    Mol Ther; 2008 Dec; 16(12):1910-8. PubMed ID: 18827807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
    Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
    J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
    Kottke T; Tonne J; Evgin L; Driscoll CB; van Vloten J; Jennings VA; Huff AL; Zell B; Thompson JM; Wongthida P; Pulido J; Schuelke MR; Samson A; Selby P; Ilett E; McNiven M; Roberts LR; Borad MJ; Pandha H; Harrington K; Melcher A; Vile RG
    Nat Commun; 2021 Mar; 12(1):1930. PubMed ID: 33772027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
    Zhang P; Han X; Tan W; Chen D; Sun Q
    Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
    Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
    Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
    Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity.
    Jiang H; Shin DH; Yi Y; Fan X; Gumin J; He J; Gillard AG; Lang FF; Gomez-Manzano C; Fueyo J
    Cancer Res Commun; 2023 Jun; 3(6):1118-1131. PubMed ID: 37379361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
    Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
    Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
    Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
    Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
    Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.
    Yarde DN; Nace RA; Russell SJ
    Exp Hematol; 2013 Dec; 41(12):1038-49. PubMed ID: 24067362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
    Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
    Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigating Macrophages Plasticity Following Tumour-Immune Interactions During Oncolytic Therapies.
    Eftimie R; Eftimie G
    Acta Biotheor; 2019 Dec; 67(4):321-359. PubMed ID: 31410657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
    Capo-chichi CD; Yeasky TM; Heiber JF; Wang Y; Barber GN; Xu XX
    Gynecol Oncol; 2010 Feb; 116(2):269-75. PubMed ID: 19932656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.
    Alonso-Camino V; Rajani K; Kottke T; Rommelfanger-Konkol D; Zaidi S; Thompson J; Pulido J; Ilett E; Donnelly O; Selby P; Pandha H; Melcher A; Harrington K; Diaz RM; Vile R
    Mol Ther; 2014 Nov; 22(11):1936-48. PubMed ID: 25059678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
    Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
    Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.